Human cystatin C in fibrotic diseases

被引:0
|
作者
Lalmanach, Gilles [1 ,2 ]
Rigoux, Baptiste [1 ,2 ]
David, Alexis [1 ,2 ]
Tahri-Joutey, Mounia [1 ,2 ,4 ]
Lecaille, Fabien [1 ,2 ]
Marchand-Adam, Sylvain [1 ,2 ,3 ]
Saidi, Ahlame [1 ,2 ]
机构
[1] Univ Tours, Tours, France
[2] Res Ctr Resp Dis CEPR, Team Proteolyt Enzymes & Their Pharmacol Targeting, INSERM, UMR1100, Tours, France
[3] Univ Hosp Ctr Tours CHRU Tours, Pulmonol Dept, Tours, France
[4] Univ La Rochelle, Inst Littoral & Environm ILE, LIENSs, UMR CNRS 7266, La Rochelle, France
基金
欧盟地平线“2020”;
关键词
Cathepsin; Cysteine protease; Extracellular matrix; Fibrosis; Glomerular filtration rate; Protease inhibitor; CYSTEINE PROTEINASE-INHIBITOR; GROWTH-FACTOR-BETA; GAMMA-TRACE; PROTEASE INHIBITORS; PULMONARY-FIBROSIS; CRYSTAL-STRUCTURE; LIVER FIBROSIS; RENAL-FUNCTION; LUNG INJURY; SERUM;
D O I
10.1016/j.cca.2024.120016
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Human cystatin C (hCC), which has a pervasive distribution within body fluids and is ubiquitously expressed by numerous cells and tissues, is a highly potent extracellular inhibitor of cysteine proteases. Besides measurement of serum creatinine, which is the most widely used technique for appraising glomerular filtration rate (GFR), hCC has emerged as a relevant GFR biomarker, because its quantification in serum is less sensitive to interferences with factors such as age, muscle mass or diet. Moreover, there are growing body of evidence that hCC overexpression and/or oversecretion, which is primarily driven by TGF-beta 1, occur during fibrogenesis (cardiac, liver, oral, and lung fibrosis). Even though molecular mechanisms and signaling pathways governing the regulation of hCC remain to be deciphered more acutely, current data sustain that hCC expression relates to myofibrogenesis and that hCC could be a specific and valuable biomarker of fibrotic disease.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Human cystatin C
    Brguljan, Pika Mesko
    Cimerman, Nina
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2007, 32 (03): : 95 - 103
  • [2] Involvement of cystatin C in pathophysiology of CNS diseases
    Nagai, Atsushi
    Terashima, Masaharu
    Sheikh, Abdullah Md
    Notsu, Yoshitomo
    Shimode, Koichi
    Yamaguchi, Shuhei
    Kobayashi, Shotai
    Kim, Seung U.
    Masuda, Junichi
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 : 3470 - 3479
  • [3] Role of Cathepsin C and Cystatin F in demyelinating diseases
    Wisessmith, W.
    Shimizu, T.
    Tanaka, K. F.
    Ikenaka, K.
    JOURNAL OF NEUROCHEMISTRY, 2014, 130 : 58 - 58
  • [4] The use of cystatin C determination in patients with neurodegenerative diseases
    Mares, J.
    Herzig, R.
    Urbanek, K.
    Vranova, H.
    Hlustik, P.
    Stejskal, D.
    Vavrouskova, J.
    Bucval, S.
    Zapletalova, J.
    Kanovsky, P.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2006, 69 (03) : 195 - 199
  • [5] Exploring the role of cathepsin C and cystatin F in demyelinating diseases
    Wisessmith, W.
    Shimizu, T.
    Tanaka, K. F.
    Chetsawang, B.
    Ikenaka, K.
    JOURNAL OF NEUROCHEMISTRY, 2012, 123 : 95 - 95
  • [6] Expression of cystatin C by human osteoclasts.
    Wucherpfennig, AL
    Li, YP
    Stashenko, P
    JOURNAL OF DENTAL RESEARCH, 1996, 75 : 2325 - 2325
  • [7] DIFFERENT FORMS OF HUMAN CYSTATIN-C
    POPOVIC, T
    BRZIN, J
    RITONJA, A
    TURK, V
    BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1990, 371 (07): : 575 - 580
  • [8] Exploring the role of cathepsin C and cystatin F in demyelinating diseases
    Wisessmith, W.
    Shimizu, T.
    Tanaka, K. F.
    Ikenaka, K.
    JOURNAL OF NEUROCHEMISTRY, 2013, 125 : 209 - 209
  • [9] The clinical usefulness of cystatin C in children with various renal diseases
    Lee, J. S.
    Shin, J. I.
    Kim, K. J.
    Kim, J. A.
    Hwang, Y. S.
    Jeong, I. C.
    Lim, J. B.
    PEDIATRIC NEPHROLOGY, 2008, 23 (09) : 1617 - 1617
  • [10] Biochemistry and clinical role of human cystatin C
    Mussap, M
    Plebani, M
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2004, 41 (5-6) : 467 - 550